Skip to content

Study · Observational study · n = 43 · 2026

5 results

Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.

Lago Garma J, Gil Mouce C, Rodríguez Novo N, Díaz Trastoy O, Santamaría Nieto A, Pérez Castro P, Díaz Ortega C, Fernández Rodríguez E, Palmeiro Carballeira R, Pinal Osorio I, Prieto Tenreiro A, Sánchez Sobrino P and 4 more

Show all authors

Tejera Pérez C, Pita Gutiérrez F, Villar Taibo R, Vidal Casariego A

Endocrinologia, diabetes y nutricion5 Feb 2026Cited by 1 (Europe PMC)

PMID41651756 (opens in a new tab)DOI10.1016/j.endien.2026.501713 (opens in a new tab)PepBankPUB-41651756
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, quality of life on the visual analog scale rose from 62.8 to 72.6 points after 3-6 months of oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, self-rated quality of life rose after 3-6 months of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseQuality of life, visual analog scale
    Study

    n = 43

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · oral · 3-6 monthsAs given in this study (human).

    Measurements

    VAS score baseline
    62.8 points
    baseline
    VAS score follow-up
    72.6 points
    3-6 months

    Source sentences

    Summary
    Oral semaglutide significantly improved quality of life according to the visual analog scale (from 62.8 to 72.6 points; p < 0.001) and DTSQ questionnaire (from 28.2 to 33.0 points; p < 0.001).
    2 context sentences
    Summary · context
    We conducted a multicenter prospective observational study Galicia (Spain).
    Summary · context
    A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the DTSQ score rose from 28.2 to 33.0 points after 3-6 months of oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, treatment satisfaction scores rose after 3-6 months of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment satisfaction, DTSQ
    Study

    n = 43

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · oral · 3-6 monthsAs given in this study (human).

    Measurements

    DTSQ baseline
    28.2 points
    baseline
    DTSQ follow-up
    33 points
    3-6 months

    Source sentences

    Summary
    Oral semaglutide significantly improved quality of life according to the visual analog scale (from 62.8 to 72.6 points; p < 0.001) and DTSQ questionnaire (from 28.2 to 33.0 points; p < 0.001).
    2 context sentences
    Summary · context
    We conducted a multicenter prospective observational study Galicia (Spain).
    Summary · context
    A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c fell from 8.3% to 7.2% after 3-6 months of oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell after 3-6 months of oral semaglutide, with no control group.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 43

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 3-6 monthsAs given in this study (human).

    Measurements

    HbA1c baseline
    8.3%
    baseline
    HbA1c follow-up
    7.2%
    3-6 months

    Source sentences

    Summary
    Significant reductions were observed in HbA1c (8.3% to 7.2%; p < 0.001)
    2 context sentences
    Summary · context
    We conducted a multicenter prospective observational study Galicia (Spain).
    Summary · context
    A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, body weight fell by 4.9% after 3-6 months of oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, body weight fell by 4.9% after 3-6 months of oral semaglutide, with no control group.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 43

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 3-6 monthsAs given in this study (human).

    Measurements

    Body weight change
    −4.9%
    3-6 months

    Source sentences

    Summary
    and body weight (-4.9%; p = 0.018).
    2 context sentences
    Summary · context
    We conducted a multicenter prospective observational study Galicia (Spain).
    Summary · context
    A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters.
  5. 05HumanObservational studySafety outcome

    In adults with type 2 diabetes on oral semaglutide, nausea and vomiting were the most common adverse effects, reported by 39.5% of patients.

    In plain wordsIn adults with type 2 diabetes on oral semaglutide, nausea and vomiting were the most common side effects, in 39.5% of patients.

    Peptide
    Semaglutide
    Outcome
    IncreaseNausea and vomiting
    Study

    n = 43

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oral · 3-6 monthsAs given in this study (human).

    Measurements

    Patients with nausea and vomiting
    39.5%
    oral semaglutide

    Source sentences

    Summary
    The most common adverse effects were nausea and vomiting, reported by 39.5% of patients, with no impact on the overall quality of life.
    2 context sentences
    Summary · context
    We conducted a multicenter prospective observational study Galicia (Spain).
    Summary · context
    A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.